What's Happening?
MiniMed Group, Inc. has announced the CE Mark approval for its MiniMed 780G system with the Instinct sensor, made by Abbott. This development expands the sensor options for users of MiniMed's advanced automated insulin delivery system. The Instinct sensor, noted
for being the world's smallest and thinnest integrated continuous glucose monitor (CGM), offers up to 15 days of wear. This system is designed to automatically adjust insulin delivery every five minutes based on real-time glucose readings, aiming to reduce the burden of diabetes management. The MiniMed 780G system is already compatible with other sensors like the Guardian 4 and Simplera Sync, which offer up to seven days of wear. The system is indicated for use by individuals with type 1 diabetes aged 7 years and older in the U.S., and for insulin-requiring type 2 diabetes aged 18 years and older, with ongoing trials for younger age groups.
Why It's Important?
The approval of the Instinct sensor for the MiniMed 780G system represents a significant advancement in diabetes management technology. By offering a longer wear time and a more discreet design, the Instinct sensor provides users with greater flexibility and convenience. This can lead to improved adherence to diabetes management protocols and potentially better health outcomes. The integration of advanced CGM technology into insulin delivery systems is crucial for reducing the frequency of high and low blood sugar episodes, thereby improving the quality of life for individuals with diabetes. The expansion of sensor options also reflects a broader trend in personalized healthcare, where patients can choose solutions that best fit their lifestyle and medical needs.
What's Next?
MiniMed plans to launch the MiniMed 780G system with the Instinct sensor in select European countries by summer 2026. The company will present the full system at the International Conference on Advanced Technologies and Treatments for Diabetes in Barcelona. In the U.S., clinical trials are underway to expand the system's use to younger children. As the system gains traction, it may influence other companies in the diabetes care market to innovate and expand their offerings, potentially leading to more competitive and advanced solutions for diabetes management.
